NO983019L - Fremgangsmåte for inhibering av fotoaldring av hud - Google Patents

Fremgangsmåte for inhibering av fotoaldring av hud

Info

Publication number
NO983019L
NO983019L NO983019A NO983019A NO983019L NO 983019 L NO983019 L NO 983019L NO 983019 A NO983019 A NO 983019A NO 983019 A NO983019 A NO 983019A NO 983019 L NO983019 L NO 983019L
Authority
NO
Norway
Prior art keywords
skin
aging
photo
exposure
uvb radiation
Prior art date
Application number
NO983019A
Other languages
English (en)
Other versions
NO983019D0 (no
Inventor
John J Voorhees
Gary J Fisher
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24355242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO983019(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of NO983019D0 publication Critical patent/NO983019D0/no
Publication of NO983019L publication Critical patent/NO983019L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Fotoelding av uskadet hud p.g.a. UVB-strålingseksponering inhiberes ved å administrere et agens som inhiberer minst en av (1) aktiviteten av UVB-strålingsinduserbare MMP-er i huden, (2) en eller begge av transkripsjonsfaktorene AP-1 og NF- B og (3) minst en av de GTP-bindende proteiner eller kinaser som er involvert i aktiveringen og/eller produksjonen av jun- eller fos-proteiner som omfatter AP-1; og topisk administrering av inhibitoren til huden forut for slik eksponering.
NO983019A 1996-01-19 1998-06-29 Fremgangsmåte for inhibering av fotoaldring av hud NO983019L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/588,771 US5837224A (en) 1996-01-19 1996-01-19 Method of inhibiting photoaging of skin
PCT/US1997/000791 WO1997025969A1 (en) 1996-01-19 1997-01-17 Method of inhibiting photoaging of skin

Publications (2)

Publication Number Publication Date
NO983019D0 NO983019D0 (no) 1998-06-29
NO983019L true NO983019L (no) 1998-08-19

Family

ID=24355242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983019A NO983019L (no) 1996-01-19 1998-06-29 Fremgangsmåte for inhibering av fotoaldring av hud

Country Status (21)

Country Link
US (1) US5837224A (no)
EP (1) EP0883398A4 (no)
JP (1) JP3705820B2 (no)
CN (1) CN1086937C (no)
AR (1) AR005650A1 (no)
BR (1) BR9707018A (no)
CA (1) CA2241981C (no)
CO (1) CO4770951A1 (no)
CZ (1) CZ291530B6 (no)
EE (1) EE9800216A (no)
HK (1) HK1018885A1 (no)
HU (1) HUP9900655A3 (no)
LT (1) LT4515B (no)
MY (1) MY119711A (no)
NO (1) NO983019L (no)
NZ (1) NZ330860A (no)
PL (1) PL327827A1 (no)
SI (1) SI9720015A (no)
SK (1) SK95998A3 (no)
TR (1) TR199801376T2 (no)
WO (1) WO1997025969A1 (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
EP1095936B1 (en) * 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Intermediates useful for the preparation of metallproteinase inhibitors
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE69828620T2 (de) * 1997-02-25 2005-12-01 The Regents Of The University Of Michigan, Ann Arbor Verfahren und zusammensetzungen zur vorbeugung und behandlung der chronologischer alterung der menschliches haut
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US20050058709A1 (en) * 1997-06-04 2005-03-17 Fisher Gary J. Methods for inhibiting photoaging of human skin using orally-administered agent
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US6683069B1 (en) * 1998-04-02 2004-01-27 Regents Of The University Of Michigan Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
FR2777183B1 (fr) * 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante
US20060212025A1 (en) 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
US6283956B1 (en) * 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
US9192780B2 (en) 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
WO2000051562A1 (en) * 1999-03-03 2000-09-08 Shiseido Company, Ltd. Matrix metalloprotease inhibitor and utilization thereof
US6602896B1 (en) * 1999-04-01 2003-08-05 The Board Of Trustees Of The University Of Arkansas p38MAPK inhibitor and uses thereof
US20040235950A1 (en) * 1999-05-20 2004-11-25 Voorhees John J. Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
EP1202747A1 (en) * 1999-07-20 2002-05-08 Merck & Co., Inc. Sustained release drug dispersion delivery device
US6982284B1 (en) 1999-09-10 2006-01-03 Applied Genetics Incorporated Dermatics Compositions and methods for modification of skin lipid content
DE19955349A1 (de) * 1999-11-17 2001-08-02 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
JP4074043B2 (ja) 2000-03-27 2008-04-09 株式会社資生堂 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
DE10020447A1 (de) * 2000-03-31 2001-10-11 Henkel Kgaa Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie
JP2004504276A (ja) * 2000-06-26 2004-02-12 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン ヒトの皮膚の光老化を防止するためのｅｇｆ−ｒタンパク質チロシンキナーゼ抑制剤の使用
CA2414247C (en) * 2000-06-29 2012-11-27 Quick-Med Technologies, Inc. Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside
US20040185127A1 (en) * 2001-06-29 2004-09-23 Lerner David S. Cosmetic composition and method
CA2413660A1 (en) 2000-07-06 2002-01-17 The Regents Of The University Of Michigan Uva (>360-400) and uvb (300-325) specific sunscreens
FR2811563B1 (fr) * 2000-07-13 2003-06-20 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes
FR2811561B1 (fr) * 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20020119107A1 (en) * 2000-12-18 2002-08-29 James Varani Method for protecting and restoring skin using selective MMP inhibitors
DE10102784A1 (de) * 2001-01-22 2002-08-01 Henkel Kgaa Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
JP2002277455A (ja) * 2001-03-15 2002-09-25 Shiseido Co Ltd 皮膚老化因子検出組成物及び検出方法
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
US7354956B2 (en) * 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
WO2003090688A2 (en) * 2002-04-24 2003-11-06 Van Andel Research Institute Enhancement of human epidermal melanogenesis
KR100920961B1 (ko) 2002-06-25 2009-10-09 가부시키가이샤 시세이도 항노화제
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7145025B2 (en) * 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
CA2531099A1 (en) 2003-04-10 2004-10-28 Light Bioscience, Llc Photomodulation methods and devices for regulating cell proliferation and gene expression
CN101247768A (zh) * 2003-07-31 2008-08-20 莱特生物科学有限公司 用于光动力学治疗烧伤、创伤和相关皮肤病的系统和方法
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
FR2858932B1 (fr) * 2003-08-22 2009-10-30 Oreal Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle
WO2005095959A2 (en) * 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060265030A1 (en) * 2004-11-12 2006-11-23 Light Bioscience, Llc System and method for photodynamic cell therapy
US8008093B2 (en) * 2004-12-02 2011-08-30 The University Of North Carolina At Chapel Hill Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders
WO2007064871A2 (en) * 2005-12-02 2007-06-07 Howard Murad Diagnostic and treatment regimen for achieving body water homeostasis
US8771647B2 (en) * 2005-12-20 2014-07-08 Kao Corporation Human photoaged skin model
US7642402B2 (en) * 2005-12-20 2010-01-05 Kao Corporation Human photoaged skin model
WO2007134219A2 (en) * 2006-05-11 2007-11-22 Living Proof, Inc. In situ polymerization for skin treatment
KR100879558B1 (ko) * 2007-07-31 2009-01-22 라이브켐 주식회사 디벤조­파라­디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제
CA2757342C (en) * 2008-04-01 2017-05-09 Biopharmacopae Design International Inc. Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
EP2276455A2 (fr) * 2008-04-22 2011-01-26 Centre National de la Recherche Scientifique Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse
JP5593323B2 (ja) 2009-09-30 2014-09-24 株式会社 資生堂 ヘパラナーゼ活性阻害剤
ES2457236T3 (es) 2009-09-30 2014-04-25 Shiseido Co., Ltd. 4-Isobutilresorcinol, como inhibidor de la actividad de la heparanasa, para prevenir o suprimir la formación de arrugas
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
JP2015221768A (ja) * 2014-05-23 2015-12-10 日本メナード化粧品株式会社 皮膚外用剤または内用剤
JP2016216435A (ja) * 2015-05-18 2016-12-22 共栄化学工業株式会社 評価方法
JP6157659B1 (ja) * 2016-02-10 2017-07-05 イノレックス インベストメント コーポレイション 紫外線誘発性脂質過酸化を低減する相乗的組成物、配合物及び関連の方法
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CN112263529A (zh) * 2020-10-27 2021-01-26 圣菲之美（湖北）生物科技有限公司 一种抗衰老组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877805A (en) * 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4603146A (en) * 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
AU610587B2 (en) * 1987-04-06 1991-05-23 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
AU636595B2 (en) * 1989-01-19 1993-05-06 Ortho Pharmaceutical Corporation Method for the treatment or prevention of intrinsically aged skin with retinoids
US5002760A (en) * 1989-10-02 1991-03-26 Katzev Phillip K Retinol skin care composition
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
AU3073692A (en) * 1991-11-25 1993-06-28 Richardson-Vicks Inc. Compositions for regulating skin wrinkles and/or skin atrophy
GR1002207B (en) * 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
WO1996023490A1 (en) * 1995-02-03 1996-08-08 Cosmederm Technologies Formulations and methods for reducing skin irritation
HUP9900925A3 (en) * 1995-06-08 2000-09-28 Johnson & Johnson Consumer Sunscreen compositions
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin

Also Published As

Publication number Publication date
HUP9900655A3 (en) 2000-09-28
HUP9900655A1 (hu) 1999-07-28
CO4770951A1 (es) 1999-04-30
NO983019D0 (no) 1998-06-29
HK1018885A1 (en) 2000-01-07
EE9800216A (et) 1999-04-15
AU1831797A (en) 1997-08-11
LT4515B (lt) 1999-06-25
WO1997025969A1 (en) 1997-07-24
AR005650A1 (es) 1999-07-14
JP2000503660A (ja) 2000-03-28
CA2241981C (en) 2002-03-19
AU701132B2 (en) 1999-01-21
CA2241981A1 (en) 1997-07-24
SK95998A3 (en) 1999-01-11
EP0883398A1 (en) 1998-12-16
SI9720015A (sl) 1999-10-31
US5837224A (en) 1998-11-17
LT98091A (en) 1999-02-25
NZ330860A (en) 1999-11-29
MY119711A (en) 2005-07-29
CZ225898A3 (cs) 1998-10-14
PL327827A1 (en) 1999-01-04
CZ291530B6 (cs) 2003-03-12
TR199801376T2 (xx) 1998-10-21
EP0883398A4 (en) 1999-05-12
CN1086937C (zh) 2002-07-03
CN1211178A (zh) 1999-03-17
BR9707018A (pt) 1999-07-20
JP3705820B2 (ja) 2005-10-12

Similar Documents

Publication Publication Date Title
NO983019L (no) Fremgangsmåte for inhibering av fotoaldring av hud
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
NO981392L (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel
NO994256L (no) Små molekyler som er anvendelige ved behandling av inflammasjonssykdom
BR9809969A (pt) Composições e método para a inibição do fotoenvelhecimento da pele
DE69326149D1 (de) (3R,4R)--g(D)?6-TETRAHYDROCANNABINOL-7-CARBONSÄUREN
ATE198601T1 (de) Ester derivate von 4-aza-steroiden
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
BR9811099A (pt) Inibidores de urocinase
NO893240D0 (no) Anvendelse av alfa-aminoborsyrederivater til profylaktisk og behandling av virussykdommer.
DK0610368T3 (da) Behandling af acne eller pseudofolliculitis barbae
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
NO911956L (no) Fremgangsmaate for fremstilling av oxydant sensitive og insensitive, aromatiske estere som inhibitorer for human neutrofil elastase
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
NO942303L (no)
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
NO984446L (no) FremgangsmÕte for behandling av smerte
ES2136581A1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
NO984197L (no) FremgangsmÕte for behandling av autisme
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
ES2160102T3 (es) Tratamiento del eritema provocado por uv.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application